WO2002030410A3 - Suppression of cyclin kinase activity for prevention and treatment of infections - Google Patents
Suppression of cyclin kinase activity for prevention and treatment of infections Download PDFInfo
- Publication number
- WO2002030410A3 WO2002030410A3 PCT/US2001/031835 US0131835W WO0230410A3 WO 2002030410 A3 WO2002030410 A3 WO 2002030410A3 US 0131835 W US0131835 W US 0131835W WO 0230410 A3 WO0230410 A3 WO 0230410A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- infections
- suppression
- prevention
- treatment
- kinase activity
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002213132A AU2002213132A1 (en) | 2000-10-10 | 2001-10-10 | Suppression of cyclin kinase activity for prevention and treatment of infections |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68598600A | 2000-10-10 | 2000-10-10 | |
US09/685,986 | 2000-10-10 | ||
US30418500P | 2000-10-11 | 2000-10-11 | |
US60/304,185 | 2000-10-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002030410A2 WO2002030410A2 (en) | 2002-04-18 |
WO2002030410A3 true WO2002030410A3 (en) | 2002-07-11 |
Family
ID=26973864
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/031835 WO2002030410A2 (en) | 2000-10-10 | 2001-10-10 | Suppression of cyclin kinase activity for prevention and treatment of infections |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002213132A1 (en) |
WO (1) | WO2002030410A2 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2616353A1 (en) * | 2005-07-28 | 2007-02-08 | University Of Massachusetts | Glucose transport-related genes, polypeptides, and methods of use thereof |
AU2022214429A1 (en) | 2021-02-01 | 2023-09-14 | Regenxbio Inc. | Gene therapy for neuronal ceroid lipofuscinoses |
CN117379432B (en) * | 2023-12-12 | 2024-03-08 | 北京大学 | Application of compound or medicinal salt thereof in preparing medicament for treating and preventing diseases caused by porcine pseudorabies virus |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002266A1 (en) * | 1984-10-12 | 1986-04-24 | United States Of America, Represented By The Unite | Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav) |
WO1990001935A1 (en) * | 1988-08-26 | 1990-03-08 | Michel Vandevelde | Use of an agent active against retrovirus and products so produced |
WO1997016447A1 (en) * | 1995-10-31 | 1997-05-09 | Mitotix, Inc. | Inhibitors of cyclin-dependent kinases |
WO1998039007A1 (en) * | 1997-03-03 | 1998-09-11 | Board Of Regents, The University Of Texas System | Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections |
WO1999030710A1 (en) * | 1997-12-13 | 1999-06-24 | Bristol-Myers Squibb Company | USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS |
WO1999062503A2 (en) * | 1998-05-29 | 1999-12-09 | Cnrs (Centre National De Recherche Scientifique) France Innovation Scientifique Et Transfert | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases |
WO2001037819A2 (en) * | 1999-11-23 | 2001-05-31 | Centre National De La Recherche Scientifique (C.N.R.S.) | Use of indirubine derivatives for making medicines |
FR2804959A1 (en) * | 2000-02-15 | 2001-08-17 | Centre Nat Rech Scient | USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS |
WO2001060367A1 (en) * | 2000-02-15 | 2001-08-23 | University Of Iowa Research Foundation | Compositions comprising flavopiridol and their use for hiv therapy |
-
2001
- 2001-10-10 AU AU2002213132A patent/AU2002213132A1/en not_active Abandoned
- 2001-10-10 WO PCT/US2001/031835 patent/WO2002030410A2/en active Search and Examination
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1986002266A1 (en) * | 1984-10-12 | 1986-04-24 | United States Of America, Represented By The Unite | Use of suramin for clinical treatment of infection with any of the members of the family of human t-cell leukemia (htlv) viruses including lymphadenopathy virus (lav) |
WO1990001935A1 (en) * | 1988-08-26 | 1990-03-08 | Michel Vandevelde | Use of an agent active against retrovirus and products so produced |
WO1997016447A1 (en) * | 1995-10-31 | 1997-05-09 | Mitotix, Inc. | Inhibitors of cyclin-dependent kinases |
WO1998039007A1 (en) * | 1997-03-03 | 1998-09-11 | Board Of Regents, The University Of Texas System | Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections |
WO1999030710A1 (en) * | 1997-12-13 | 1999-06-24 | Bristol-Myers Squibb Company | USE OF PYRAZOLO [3,4-b] PYRIDINE AS CYCLIN DEPENDENT KINASE INHIBITORS |
WO1999062503A2 (en) * | 1998-05-29 | 1999-12-09 | Cnrs (Centre National De Recherche Scientifique) France Innovation Scientifique Et Transfert | Use of indigoid bisindole derivatives for the manufacture of a medicament to inhibit cyclin dependent kinases |
WO2001037819A2 (en) * | 1999-11-23 | 2001-05-31 | Centre National De La Recherche Scientifique (C.N.R.S.) | Use of indirubine derivatives for making medicines |
FR2804959A1 (en) * | 2000-02-15 | 2001-08-17 | Centre Nat Rech Scient | USE OF PAULLON DERIVATIVES FOR THE MANUFACTURE OF MEDICAMENTS |
WO2001060367A1 (en) * | 2000-02-15 | 2001-08-23 | University Of Iowa Research Foundation | Compositions comprising flavopiridol and their use for hiv therapy |
Non-Patent Citations (13)
Title |
---|
BRESNAHAN W A ET AL: "INHIBITION OF CELLULAR CDK2 ACTIVITY BLOCKS HUMAN CYTOMEGALOVIRUS REPLICATION", VIROLOGY, ACADEMIC PRESS,ORLANDO, US, vol. 231, 1997, pages 239 - 247, XP002922856, ISSN: 0042-6822 * |
CHAO S-H ET AL: "FLAVOPIRIDOL INHIBITS P-TEFB AND BLOCKS HIV-1 REPLICATION", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 275, no. 37, 15 September 2000 (2000-09-15), pages 28345 - 28348, XP000986289, ISSN: 0021-9258 * |
GRAESER, R. ET AL.: "Plasmodium falciparum protein kinase 5 and the malarial nuclear division cycles", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 82, no. 1, 12 November 1996 (1996-11-12), pages 37 - 49, XP001069211 * |
GRAY N ET AL: "ATP-SITE DIRECTED INHIBITORS OF CYCLIN-DEPENDENT KINASES", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 9, September 1999 (1999-09-01), pages 859 - 875, XP000856195, ISSN: 0929-8673 * |
KITAGAWA, M. ET AL: "A cyclin-dependent kinase inhibitor, butyrolactone I, inhibits phosphorylation of RB protein and cell cycle progression", ONCOGENE, vol. 9, no. 9, September 1994 (1994-09-01), pages 2549 - 2557, XP001069210 * |
KNOCKAERT, M. ET AL.: "Intracellular targetsof cyclin-dependent kinase inhibitors: identification by affinity chromatography using immobilised inhibitors", CHEMISTRY AND BIOLOGY, vol. 7, no. 6, June 2000 (2000-06-01), UK, pages 411 - 422, XP001070114 * |
MEIJER L ET AL: "INHIBITION OF CYCLIN-DEPENDENT KINASES, GSK-3SS AND CK1 BY HYMENIALDISINE, A MARINE SPONGE CONSTITUENT", CHEMISTRY AND BIOLOGY, CURRENT BIOLOGY, LONDON, GB, vol. 7, no. 1, January 2000 (2000-01-01), pages 51 - 63, XP000901413, ISSN: 1074-5521 * |
MEIJER L: "CYCLIN-DEPENDENT KINASES INHIBITORS AS POTENTIAL ANTICANCER, ANTINEURODEGENERATIVE, ANTIVIRAL AND ANTIPARASITIC AGENTS", DRUG RESISTANCE UPDATES, CHURCHILL LIVINGSTONE, EDINBURGH, GB, vol. 3, no. 2, 2000, pages 83 - 88, XP000931278, ISSN: 1368-7646 * |
SCHANG L M ET AL: "REQUIREMENT FOR CELLULAR CYCLIN-DEPENDENT KINASES IN HERPES SIMPLEXVIRUS REPLICATION AND TRANSCRIPTION", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 72, no. 7, 1998, pages 5626 - 5637, XP000909412, ISSN: 0022-538X * |
SHANG, L., M. ET AL.: "Roscovitine, a specific Inhibitor of Cellular Cyclin-Dependent Kinases,, Inhibits Herpes Simplex Virus DNA Synthesis in the presence of Viral Early Proteins", JOURNAL OF VIROLOGY, vol. 74, no. 5, March 2000 (2000-03-01), USA, pages 2107 - 2120, XP001070109 * |
SHANG, L., M. ET AL.: "Transcription of Herpes Simplex Virus Immediate-Early and Early Genes Is Inhibited by Roscovitine, an Inhibitor Specific for Cellular Cyclin-Dependent Kinases", JOURNAL OF VIROLOGY, vol. 73, no. 3, March 1999 (1999-03-01), USA, pages 2161 - 2172, XP001070110 * |
VEERANNA ET AL.: "Inhibition of Neuronal Cyclin-Dependent Kinase-5 by Staurosporine and Purine Analogs is Independent of Activation by Munc-18", NEUROCHEMICAL RESEARCH, vol. 21, no. 5, May 1996 (1996-05-01), pages 629 - 636, XP001069208 * |
WATERS N.C. ET AL.: "Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum", MOLECULAR AND BIOCHEMICAL PARASITOLOGY, vol. 107, 2000, pages 45 - 55, XP001069206 * |
Also Published As
Publication number | Publication date |
---|---|
AU2002213132A1 (en) | 2002-04-22 |
WO2002030410A2 (en) | 2002-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003274071A1 (en) | Dosage form that is safeguarded from abuse | |
WO2006047716A3 (en) | Use of diindolylmethane-related indoles and growth factor receptor inhibitors for the treatment of human cytomegalovirus associated disease | |
WO2002085857A3 (en) | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas | |
NO985856L (en) | Absorbent objects that breathe and have odor control | |
AU2003291342A1 (en) | Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof | |
IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
EP1003519A4 (en) | Supression of cyclin kinase 2 activity for prevention and treatment of dna viral infections | |
DE60132851D1 (en) | Medicines for the prevention, alleviation or treatment of hypertension | |
WO2002006513A3 (en) | A method for treating herpes viruses | |
CA2245123A1 (en) | Use of rosaceae plant extract as a bradykinin antagonist | |
WO2003053360A3 (en) | Treatment of ebv and khsv infection and associated abnormal cellular proliferation | |
DE69624243D1 (en) | USE OF INDIGESTIBLE OLIGOSACCHARIDES FOR THE PREVENTION AND TREATMENT OF MEDIUM-EARTH IGNITION IN PEOPLE | |
CA2418167A1 (en) | Compositions and methods of preventing or reducing the risk or incidence of skeletal injuries in horses | |
WO2002030410A3 (en) | Suppression of cyclin kinase activity for prevention and treatment of infections | |
WO2005040989A3 (en) | Tactile input system | |
AUPQ622600A0 (en) | Treatment and/or prevention of ocular pain | |
AU2476200A (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
WO1996002240A3 (en) | Use of inhibitors of human s-cd23 | |
MX9601149A (en) | Use of a calcitonine gene-derived peptide antagonist for the treatment of pruritus and ocular and palpebral dysaesthesias, and composition including said antagonist. | |
EP0992243A4 (en) | Prophylactic/remedial agent | |
HK1061209A1 (en) | Use of the long pentraxin ptx3 for the treatment of diseases caused by an altered activation of the growth factor fgf-2 | |
WO2001070737A3 (en) | Therapeutic heterocyclic compounds for the treatment of asthma and allergy and use thereof | |
AU2379997A (en) | Remedy for external application, and use of an oil-in-water emulsion for said remedy | |
DK0722325T3 (en) | Preparation for the treatment or prevention of herpes | |
WO2003045428A3 (en) | Use of a technically modified cell as a vaccine for treating tumoral disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
DPE2 | Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101) |